American Academy of Dermatology Meeting

American Academy of Dermatology Meeting

Source:

Smith SD, et al. Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate-to-severe psoriasis: 24-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H). Presented at: AAD VMX; June 12-14, 2020 (virtual meeting).

Disclosures: Smith reports he is on the advisory panel for AbbVie, Biogen, Eli Lilly and Company, Janssen-Cilag, Johnson & Johnson Consumer Products Company, Novartis, Pfizer and Sanofi Genzyme; receives research support from AbbVie, BMS, Eli Lilly and Company, Novartis, Sanofi Genzyme, UCB and Regeneron; is on the speakers bureau for AbbVie, Eli Lilly and Company, Leo and Novartis; and receives honoraria from Energizer Holdings. Please see the study for all other authors’ relevant financial disclosures.
August 26, 2020
1 min read
Save

Better resolution of nail psoriasis seen with ixekizumab than adalimumab

Source:

Smith SD, et al. Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate-to-severe psoriasis: 24-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H). Presented at: AAD VMX; June 12-14, 2020 (virtual meeting).

Disclosures: Smith reports he is on the advisory panel for AbbVie, Biogen, Eli Lilly and Company, Janssen-Cilag, Johnson & Johnson Consumer Products Company, Novartis, Pfizer and Sanofi Genzyme; receives research support from AbbVie, BMS, Eli Lilly and Company, Novartis, Sanofi Genzyme, UCB and Regeneron; is on the speakers bureau for AbbVie, Eli Lilly and Company, Leo and Novartis; and receives honoraria from Energizer Holdings. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ixekizumab showed a significantly higher rate of resolving nail psoriasis compared with adalimumab, according to a study poster presented at the American Academy of Dermatology virtual meeting.

A post hoc subgroup analysis of the SPIRIT-H2H study included 100 subjects with moderate to severe psoriasis with a Psoriasis Area and Severity Index score of 12 or higher, a static Physician’s Global Assessment score of 3 or higher and Body Surface Area involvement of 10% or more, while 78 subjects had nail psoriasis with a baseline Nail Psoriasis Severity Index (NAPSI) fingernails score of 1 or higher.

At week 16, 59.5% of those treated with ixekizumab had complete resolution of nail psoriasis compared with 48.8% of those treated with adalimumab. Those percentages rose to 64.9% and 58.5%, respectively, at week 16 and 80% and 52.5%, respectively, at week 24.

The difference between the two groups in least squares mean change in NAPSI baseline score was –4.4 at week 24.

“In this post hoc analysis, [ixekizumab] showed significantly higher rates of complete resolution of nail involvement than [adalimumab] at week 24, confirming the established efficacy of [ixekizumab] in nail psoriasis,” the study authors wrote.